Pneumonia risk stratification in tropical Australia: does the SMART-COP score apply?

Med J Aust. 2010 Feb 1;192(3):133-6. doi: 10.5694/j.1326-5377.2010.tb03450.x.

Abstract

Objective: To examine the performance in tropical northern Australia of SMART-COP, a simple scoring system developed in temperate Australia to predict the need for intensive respiratory or vasopressor support (IRVS) in pneumonia patients.

Design, setting and patients: A prospective observational study of patients admitted to Royal Darwin Hospital in the Northern Territory with sepsis between August 2007 and May 2008. Chest x-rays were reviewed to confirm pneumonia, and each patient's SMART-COP score was assessed against the need for IRVS.

Results: Of 206 patients presenting with radiologically confirmed pneumonia, 184 were eligible for inclusion. The mean age of patients was 50.1 years, 65% were Indigenous and 56% were men. Overall, 38 patients (21%) required IRVS, and 18 patients (10%) died by Day 30. A SMART-COP score of >or= 3 had a sensitivity of only 71% for predicting the need for IRVS and 67% for 30-day mortality. As the variables most strongly associated with IRVS were serum albumin level < 35 g/L (odds ratio, 6.8) and Indigenous status (odds ratio, 2.3), we tested a modified scoring system (SMART-COP) that used a higher weighting for albumin and included Indigenous status. A SMART-COP score of >or= 3 had a sensitivity of 97% for IRVS and 100% for 30-day mortality.

Conclusions: The SMART-COP score underestimates the severity of pneumonia in tropical northern Australia, but can be improved by using locally relevant additions.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Australia
  • Community-Acquired Infections / diagnosis
  • Community-Acquired Infections / etiology
  • Community-Acquired Infections / therapy
  • Female
  • Humans
  • Male
  • Middle Aged
  • Pneumonia / diagnosis*
  • Pneumonia / etiology
  • Pneumonia / therapy*
  • Predictive Value of Tests
  • Prospective Studies
  • Respiration, Artificial
  • Risk Assessment
  • Severity of Illness Index*
  • Tropical Climate*
  • Vasoconstrictor Agents / therapeutic use

Substances

  • Vasoconstrictor Agents